nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCG2—Cladribine—multiple sclerosis	0.0635	0.139	CbGbCtD
Ponatinib—ABCB11—Dexamethasone—multiple sclerosis	0.0505	0.111	CbGbCtD
Ponatinib—ABCG2—Mitoxantrone—multiple sclerosis	0.0463	0.101	CbGbCtD
Ponatinib—CYP2D6—Fingolimod—multiple sclerosis	0.0335	0.0733	CbGbCtD
Ponatinib—ABCG2—Dexamethasone—multiple sclerosis	0.024	0.0526	CbGbCtD
Ponatinib—ABCB1—Methylprednisolone—multiple sclerosis	0.0229	0.0501	CbGbCtD
Ponatinib—CYP3A4—Fingolimod—multiple sclerosis	0.0213	0.0466	CbGbCtD
Ponatinib—ABCG2—Methotrexate—multiple sclerosis	0.0193	0.0423	CbGbCtD
Ponatinib—ABCB1—Mitoxantrone—multiple sclerosis	0.0167	0.0366	CbGbCtD
Ponatinib—ABCB1—Betamethasone—multiple sclerosis	0.0149	0.0326	CbGbCtD
Ponatinib—ABCB1—Prednisolone—multiple sclerosis	0.0147	0.0322	CbGbCtD
Ponatinib—ABCB1—Prednisone—multiple sclerosis	0.0139	0.0304	CbGbCtD
Ponatinib—CYP3A4—Methylprednisolone—multiple sclerosis	0.0137	0.03	CbGbCtD
Ponatinib—CYP3A5—Dexamethasone—multiple sclerosis	0.0133	0.0291	CbGbCtD
Ponatinib—CYP2C8—Dexamethasone—multiple sclerosis	0.0128	0.028	CbGbCtD
Ponatinib—CYP3A4—Triamcinolone—multiple sclerosis	0.0104	0.0228	CbGbCtD
Ponatinib—CYP3A4—Mitoxantrone—multiple sclerosis	0.01	0.0219	CbGbCtD
Ponatinib—CYP3A4—Betamethasone—multiple sclerosis	0.00892	0.0195	CbGbCtD
Ponatinib—CYP3A4—Prednisolone—multiple sclerosis	0.0088	0.0193	CbGbCtD
Ponatinib—ABCB1—Dexamethasone—multiple sclerosis	0.00866	0.019	CbGbCtD
Ponatinib—CYP3A4—Prednisone—multiple sclerosis	0.00831	0.0182	CbGbCtD
Ponatinib—CYP2D6—Dexamethasone—multiple sclerosis	0.00816	0.0179	CbGbCtD
Ponatinib—ABCB1—Methotrexate—multiple sclerosis	0.00696	0.0152	CbGbCtD
Ponatinib—CYP3A4—Dexamethasone—multiple sclerosis	0.00519	0.0114	CbGbCtD
Ponatinib—FGFR4—brainstem—multiple sclerosis	0.00353	0.0413	CbGeAlD
Ponatinib—FGFR4—nervous system—multiple sclerosis	0.00185	0.0216	CbGeAlD
Ponatinib—FGFR4—central nervous system—multiple sclerosis	0.00178	0.0208	CbGeAlD
Ponatinib—FGFR4—cerebellum—multiple sclerosis	0.00174	0.0204	CbGeAlD
Ponatinib—FGFR3—medulla oblongata—multiple sclerosis	0.00168	0.0196	CbGeAlD
Ponatinib—FGFR2—brainstem—multiple sclerosis	0.00158	0.0184	CbGeAlD
Ponatinib—FGFR3—midbrain—multiple sclerosis	0.00153	0.018	CbGeAlD
Ponatinib—FGFR3—spinal cord—multiple sclerosis	0.0015	0.0175	CbGeAlD
Ponatinib—BCR—medulla oblongata—multiple sclerosis	0.00145	0.017	CbGeAlD
Ponatinib—FGFR4—brain—multiple sclerosis	0.00141	0.0165	CbGeAlD
Ponatinib—BCR—midbrain—multiple sclerosis	0.00133	0.0155	CbGeAlD
Ponatinib—BCR—spinal cord—multiple sclerosis	0.0013	0.0152	CbGeAlD
Ponatinib—SRC—retina—multiple sclerosis	0.0013	0.0152	CbGeAlD
Ponatinib—FGFR1—medulla oblongata—multiple sclerosis	0.00129	0.0151	CbGeAlD
Ponatinib—LYN—nervous system—multiple sclerosis	0.00127	0.0148	CbGeAlD
Ponatinib—FGFR3—nervous system—multiple sclerosis	0.00126	0.0148	CbGeAlD
Ponatinib—LYN—central nervous system—multiple sclerosis	0.00122	0.0143	CbGeAlD
Ponatinib—FGFR3—central nervous system—multiple sclerosis	0.00121	0.0142	CbGeAlD
Ponatinib—KDR—retina—multiple sclerosis	0.00119	0.0139	CbGeAlD
Ponatinib—FGFR3—cerebellum—multiple sclerosis	0.00119	0.0139	CbGeAlD
Ponatinib—FGFR1—midbrain—multiple sclerosis	0.00118	0.0138	CbGeAlD
Ponatinib—RET—medulla oblongata—multiple sclerosis	0.00116	0.0135	CbGeAlD
Ponatinib—FGFR1—spinal cord—multiple sclerosis	0.00115	0.0135	CbGeAlD
Ponatinib—KIT—brainstem—multiple sclerosis	0.00109	0.0128	CbGeAlD
Ponatinib—BCR—nervous system—multiple sclerosis	0.00109	0.0128	CbGeAlD
Ponatinib—RET—midbrain—multiple sclerosis	0.00106	0.0124	CbGeAlD
Ponatinib—TEK—medulla oblongata—multiple sclerosis	0.00105	0.0123	CbGeAlD
Ponatinib—BCR—central nervous system—multiple sclerosis	0.00105	0.0123	CbGeAlD
Ponatinib—RET—spinal cord—multiple sclerosis	0.00103	0.0121	CbGeAlD
Ponatinib—BCR—cerebellum—multiple sclerosis	0.00103	0.012	CbGeAlD
Ponatinib—FLT3—cerebellum—multiple sclerosis	0.00102	0.0119	CbGeAlD
Ponatinib—FGFR2—spinal cord—multiple sclerosis	0.00098	0.0115	CbGeAlD
Ponatinib—LYN—brain—multiple sclerosis	0.000969	0.0113	CbGeAlD
Ponatinib—FGFR3—brain—multiple sclerosis	0.000964	0.0113	CbGeAlD
Ponatinib—TEK—midbrain—multiple sclerosis	0.000963	0.0113	CbGeAlD
Ponatinib—ABL1—brainstem—multiple sclerosis	0.000953	0.0111	CbGeAlD
Ponatinib—TEK—spinal cord—multiple sclerosis	0.000939	0.011	CbGeAlD
Ponatinib—ABL1—retina—multiple sclerosis	0.000919	0.0108	CbGeAlD
Ponatinib—FGFR1—cerebellum—multiple sclerosis	0.000914	0.0107	CbGeAlD
Ponatinib—RET—nervous system—multiple sclerosis	0.000869	0.0102	CbGeAlD
Ponatinib—KDR—medulla oblongata—multiple sclerosis	0.000861	0.0101	CbGeAlD
Ponatinib—PDGFRA—spinal cord—multiple sclerosis	0.000851	0.00996	CbGeAlD
Ponatinib—RET—central nervous system—multiple sclerosis	0.000837	0.00979	CbGeAlD
Ponatinib—SRC—spinal cord—multiple sclerosis	0.000835	0.00977	CbGeAlD
Ponatinib—BCR—brain—multiple sclerosis	0.000834	0.00976	CbGeAlD
Ponatinib—FGFR2—nervous system—multiple sclerosis	0.000826	0.00966	CbGeAlD
Ponatinib—RET—cerebellum—multiple sclerosis	0.000818	0.00957	CbGeAlD
Ponatinib—FGFR2—central nervous system—multiple sclerosis	0.000795	0.0093	CbGeAlD
Ponatinib—TEK—nervous system—multiple sclerosis	0.000792	0.00926	CbGeAlD
Ponatinib—KDR—midbrain—multiple sclerosis	0.000787	0.00921	CbGeAlD
Ponatinib—FGFR2—cerebellum—multiple sclerosis	0.000777	0.00909	CbGeAlD
Ponatinib—KDR—spinal cord—multiple sclerosis	0.000768	0.00898	CbGeAlD
Ponatinib—KIT—medulla oblongata—multiple sclerosis	0.000763	0.00893	CbGeAlD
Ponatinib—TEK—central nervous system—multiple sclerosis	0.000762	0.00892	CbGeAlD
Ponatinib—TEK—cerebellum—multiple sclerosis	0.000745	0.00872	CbGeAlD
Ponatinib—FGFR1—brain—multiple sclerosis	0.000742	0.00869	CbGeAlD
Ponatinib—PDGFRA—nervous system—multiple sclerosis	0.000717	0.00839	CbGeAlD
Ponatinib—SRC—nervous system—multiple sclerosis	0.000703	0.00823	CbGeAlD
Ponatinib—KIT—midbrain—multiple sclerosis	0.000697	0.00816	CbGeAlD
Ponatinib—PDGFRA—central nervous system—multiple sclerosis	0.00069	0.00808	CbGeAlD
Ponatinib—KIT—spinal cord—multiple sclerosis	0.00068	0.00796	CbGeAlD
Ponatinib—SRC—central nervous system—multiple sclerosis	0.000677	0.00792	CbGeAlD
Ponatinib—PDGFRA—cerebellum—multiple sclerosis	0.000675	0.0079	CbGeAlD
Ponatinib—ABL1—medulla oblongata—multiple sclerosis	0.000664	0.00777	CbGeAlD
Ponatinib—RET—brain—multiple sclerosis	0.000664	0.00777	CbGeAlD
Ponatinib—SRC—cerebellum—multiple sclerosis	0.000662	0.00774	CbGeAlD
Ponatinib—KDR—nervous system—multiple sclerosis	0.000647	0.00757	CbGeAlD
Ponatinib—FGFR2—brain—multiple sclerosis	0.000631	0.00738	CbGeAlD
Ponatinib—KDR—central nervous system—multiple sclerosis	0.000623	0.00729	CbGeAlD
Ponatinib—KDR—cerebellum—multiple sclerosis	0.000609	0.00712	CbGeAlD
Ponatinib—ABL1—midbrain—multiple sclerosis	0.000607	0.0071	CbGeAlD
Ponatinib—TEK—brain—multiple sclerosis	0.000605	0.00708	CbGeAlD
Ponatinib—ABL1—spinal cord—multiple sclerosis	0.000592	0.00693	CbGeAlD
Ponatinib—KIT—nervous system—multiple sclerosis	0.000573	0.00671	CbGeAlD
Ponatinib—KIT—central nervous system—multiple sclerosis	0.000552	0.00646	CbGeAlD
Ponatinib—PDGFRA—brain—multiple sclerosis	0.000548	0.00641	CbGeAlD
Ponatinib—KIT—cerebellum—multiple sclerosis	0.00054	0.00631	CbGeAlD
Ponatinib—SRC—brain—multiple sclerosis	0.000538	0.00629	CbGeAlD
Ponatinib—ABL1—nervous system—multiple sclerosis	0.000499	0.00584	CbGeAlD
Ponatinib—KDR—brain—multiple sclerosis	0.000495	0.00579	CbGeAlD
Ponatinib—ABL1—central nervous system—multiple sclerosis	0.000481	0.00562	CbGeAlD
Ponatinib—ABL1—cerebellum—multiple sclerosis	0.00047	0.0055	CbGeAlD
Ponatinib—KIT—brain—multiple sclerosis	0.000438	0.00513	CbGeAlD
Ponatinib—ABCG2—medulla oblongata—multiple sclerosis	0.000419	0.0049	CbGeAlD
Ponatinib—CYP2D6—brainstem—multiple sclerosis	0.000412	0.00482	CbGeAlD
Ponatinib—ABCG2—midbrain—multiple sclerosis	0.000383	0.00448	CbGeAlD
Ponatinib—ABL1—brain—multiple sclerosis	0.000381	0.00446	CbGeAlD
Ponatinib—ABCG2—spinal cord—multiple sclerosis	0.000374	0.00437	CbGeAlD
Ponatinib—ABCG2—cerebellum—multiple sclerosis	0.000296	0.00347	CbGeAlD
Ponatinib—ABCB1—retina—multiple sclerosis	0.000286	0.00334	CbGeAlD
Ponatinib—CYP2C8—brain—multiple sclerosis	0.000247	0.0029	CbGeAlD
Ponatinib—ABCG2—brain—multiple sclerosis	0.000241	0.00282	CbGeAlD
Ponatinib—CYP3A4—nervous system—multiple sclerosis	0.000219	0.00257	CbGeAlD
Ponatinib—CYP2D6—nervous system—multiple sclerosis	0.000216	0.00252	CbGeAlD
Ponatinib—CYP3A4—central nervous system—multiple sclerosis	0.000211	0.00247	CbGeAlD
Ponatinib—CYP2D6—central nervous system—multiple sclerosis	0.000208	0.00243	CbGeAlD
Ponatinib—ABCB1—medulla oblongata—multiple sclerosis	0.000207	0.00242	CbGeAlD
Ponatinib—CYP2D6—cerebellum—multiple sclerosis	0.000203	0.00238	CbGeAlD
Ponatinib—ABCB1—midbrain—multiple sclerosis	0.000189	0.00221	CbGeAlD
Ponatinib—ABCB1—spinal cord—multiple sclerosis	0.000184	0.00216	CbGeAlD
Ponatinib—CYP2D6—brain—multiple sclerosis	0.000165	0.00193	CbGeAlD
Ponatinib—Neuropathy peripheral—Prednisone—multiple sclerosis	0.00016	0.000723	CcSEcCtD
Ponatinib—Breast disorder—Methotrexate—multiple sclerosis	0.00016	0.000723	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000159	0.000719	CcSEcCtD
Ponatinib—Nausea—Cladribine—multiple sclerosis	0.000158	0.000713	CcSEcCtD
Ponatinib—Eye disorder—Dexamethasone—multiple sclerosis	0.000157	0.000711	CcSEcCtD
Ponatinib—Eye disorder—Betamethasone—multiple sclerosis	0.000157	0.000711	CcSEcCtD
Ponatinib—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000157	0.000709	CcSEcCtD
Ponatinib—Back pain—Triamcinolone—multiple sclerosis	0.000156	0.000706	CcSEcCtD
Ponatinib—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000156	0.000704	CcSEcCtD
Ponatinib—ABCB1—nervous system—multiple sclerosis	0.000155	0.00182	CbGeAlD
Ponatinib—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000154	0.000695	CcSEcCtD
Ponatinib—Angiopathy—Betamethasone—multiple sclerosis	0.000153	0.00069	CcSEcCtD
Ponatinib—Angiopathy—Dexamethasone—multiple sclerosis	0.000153	0.00069	CcSEcCtD
Ponatinib—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000152	0.000686	CcSEcCtD
Ponatinib—Hypertension—Prednisolone—multiple sclerosis	0.000151	0.000685	CcSEcCtD
Ponatinib—Fatigue—Mitoxantrone—multiple sclerosis	0.00015	0.00068	CcSEcCtD
Ponatinib—Arrhythmia—Dexamethasone—multiple sclerosis	0.00015	0.000679	CcSEcCtD
Ponatinib—Arrhythmia—Betamethasone—multiple sclerosis	0.00015	0.000679	CcSEcCtD
Ponatinib—Pancreatitis—Methotrexate—multiple sclerosis	0.00015	0.000678	CcSEcCtD
Ponatinib—ABCB1—central nervous system—multiple sclerosis	0.000149	0.00175	CbGeAlD
Ponatinib—Pain—Mitoxantrone—multiple sclerosis	0.000149	0.000675	CcSEcCtD
Ponatinib—Constipation—Mitoxantrone—multiple sclerosis	0.000149	0.000675	CcSEcCtD
Ponatinib—Alopecia—Betamethasone—multiple sclerosis	0.000149	0.000672	CcSEcCtD
Ponatinib—Alopecia—Dexamethasone—multiple sclerosis	0.000149	0.000672	CcSEcCtD
Ponatinib—Diarrhoea—Azathioprine—multiple sclerosis	0.000148	0.000668	CcSEcCtD
Ponatinib—Haemoglobin—Prednisone—multiple sclerosis	0.000147	0.000666	CcSEcCtD
Ponatinib—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000147	0.000663	CcSEcCtD
Ponatinib—Haemorrhage—Prednisone—multiple sclerosis	0.000146	0.000662	CcSEcCtD
Ponatinib—Erythema—Betamethasone—multiple sclerosis	0.000146	0.000662	CcSEcCtD
Ponatinib—Erythema—Dexamethasone—multiple sclerosis	0.000146	0.000662	CcSEcCtD
Ponatinib—ABCB1—cerebellum—multiple sclerosis	0.000146	0.00171	CbGeAlD
Ponatinib—Pancytopenia—Methotrexate—multiple sclerosis	0.000145	0.000657	CcSEcCtD
Ponatinib—Connective tissue disorder—Prednisone—multiple sclerosis	0.000144	0.000651	CcSEcCtD
Ponatinib—Oedema—Prednisolone—multiple sclerosis	0.000143	0.000647	CcSEcCtD
Ponatinib—Neutropenia—Methotrexate—multiple sclerosis	0.000143	0.000647	CcSEcCtD
Ponatinib—Dizziness—Azathioprine—multiple sclerosis	0.000143	0.000646	CcSEcCtD
Ponatinib—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000143	0.000645	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000142	0.000643	CcSEcCtD
Ponatinib—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000141	0.000637	CcSEcCtD
Ponatinib—Cough—Triamcinolone—multiple sclerosis	0.000141	0.000637	CcSEcCtD
Ponatinib—Hypertension—Triamcinolone—multiple sclerosis	0.000139	0.00063	CcSEcCtD
Ponatinib—Hypertension—Methylprednisolone—multiple sclerosis	0.000139	0.000628	CcSEcCtD
Ponatinib—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000138	0.000626	CcSEcCtD
Ponatinib—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000138	0.000624	CcSEcCtD
Ponatinib—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000138	0.000624	CcSEcCtD
Ponatinib—Myalgia—Triamcinolone—multiple sclerosis	0.000137	0.000621	CcSEcCtD
Ponatinib—Vomiting—Azathioprine—multiple sclerosis	0.000137	0.000621	CcSEcCtD
Ponatinib—Pneumonia—Methotrexate—multiple sclerosis	0.000137	0.00062	CcSEcCtD
Ponatinib—Arthralgia—Methylprednisolone—multiple sclerosis	0.000137	0.00062	CcSEcCtD
Ponatinib—Myalgia—Methylprednisolone—multiple sclerosis	0.000137	0.00062	CcSEcCtD
Ponatinib—Eye disorder—Prednisone—multiple sclerosis	0.000137	0.000619	CcSEcCtD
Ponatinib—Infestation NOS—Methotrexate—multiple sclerosis	0.000136	0.000616	CcSEcCtD
Ponatinib—Infestation—Methotrexate—multiple sclerosis	0.000136	0.000616	CcSEcCtD
Ponatinib—Rash—Azathioprine—multiple sclerosis	0.000136	0.000615	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000136	0.000615	CcSEcCtD
Ponatinib—Dermatitis—Azathioprine—multiple sclerosis	0.000136	0.000615	CcSEcCtD
Ponatinib—Flushing—Prednisone—multiple sclerosis	0.000136	0.000615	CcSEcCtD
Ponatinib—Headache—Azathioprine—multiple sclerosis	0.000135	0.000612	CcSEcCtD
Ponatinib—Dry mouth—Triamcinolone—multiple sclerosis	0.000134	0.000607	CcSEcCtD
Ponatinib—Stomatitis—Methotrexate—multiple sclerosis	0.000133	0.000601	CcSEcCtD
Ponatinib—Angiopathy—Prednisone—multiple sclerosis	0.000133	0.000601	CcSEcCtD
Ponatinib—Oedema—Triamcinolone—multiple sclerosis	0.000132	0.000595	CcSEcCtD
Ponatinib—Arrhythmia—Prednisone—multiple sclerosis	0.000131	0.000592	CcSEcCtD
Ponatinib—Infection—Triamcinolone—multiple sclerosis	0.000131	0.000591	CcSEcCtD
Ponatinib—Infection—Methylprednisolone—multiple sclerosis	0.000131	0.00059	CcSEcCtD
Ponatinib—Insomnia—Prednisolone—multiple sclerosis	0.00013	0.000586	CcSEcCtD
Ponatinib—Alopecia—Prednisone—multiple sclerosis	0.000129	0.000585	CcSEcCtD
Ponatinib—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000129	0.000583	CcSEcCtD
Ponatinib—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000129	0.000583	CcSEcCtD
Ponatinib—Epistaxis—Methotrexate—multiple sclerosis	0.000129	0.000581	CcSEcCtD
Ponatinib—Paraesthesia—Prednisolone—multiple sclerosis	0.000129	0.000581	CcSEcCtD
Ponatinib—Mental disorder—Prednisone—multiple sclerosis	0.000128	0.00058	CcSEcCtD
Ponatinib—Nausea—Azathioprine—multiple sclerosis	0.000128	0.00058	CcSEcCtD
Ponatinib—Skin disorder—Methylprednisolone—multiple sclerosis	0.000128	0.000577	CcSEcCtD
Ponatinib—Erythema—Prednisone—multiple sclerosis	0.000127	0.000576	CcSEcCtD
Ponatinib—Malnutrition—Prednisone—multiple sclerosis	0.000127	0.000576	CcSEcCtD
Ponatinib—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000127	0.000576	CcSEcCtD
Ponatinib—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000127	0.000574	CcSEcCtD
Ponatinib—Hypertension—Betamethasone—multiple sclerosis	0.000126	0.000571	CcSEcCtD
Ponatinib—Hypertension—Dexamethasone—multiple sclerosis	0.000126	0.000571	CcSEcCtD
Ponatinib—Asthenia—Mitoxantrone—multiple sclerosis	0.000125	0.000566	CcSEcCtD
Ponatinib—Myalgia—Dexamethasone—multiple sclerosis	0.000125	0.000564	CcSEcCtD
Ponatinib—Myalgia—Betamethasone—multiple sclerosis	0.000125	0.000564	CcSEcCtD
Ponatinib—Haemoglobin—Methotrexate—multiple sclerosis	0.000123	0.000556	CcSEcCtD
Ponatinib—Pain—Prednisolone—multiple sclerosis	0.000122	0.000554	CcSEcCtD
Ponatinib—Haemorrhage—Methotrexate—multiple sclerosis	0.000122	0.000553	CcSEcCtD
Ponatinib—Vision blurred—Prednisone—multiple sclerosis	0.00012	0.000543	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.00012	0.000542	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.00012	0.000541	CcSEcCtD
Ponatinib—Oedema—Betamethasone—multiple sclerosis	0.000119	0.00054	CcSEcCtD
Ponatinib—Oedema—Dexamethasone—multiple sclerosis	0.000119	0.00054	CcSEcCtD
Ponatinib—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000119	0.00054	CcSEcCtD
Ponatinib—Insomnia—Triamcinolone—multiple sclerosis	0.000119	0.000538	CcSEcCtD
Ponatinib—Insomnia—Methylprednisolone—multiple sclerosis	0.000119	0.000537	CcSEcCtD
Ponatinib—Infection—Betamethasone—multiple sclerosis	0.000119	0.000537	CcSEcCtD
Ponatinib—Infection—Dexamethasone—multiple sclerosis	0.000119	0.000537	CcSEcCtD
Ponatinib—ABCB1—brain—multiple sclerosis	0.000119	0.00139	CbGeAlD
Ponatinib—Paraesthesia—Triamcinolone—multiple sclerosis	0.000118	0.000535	CcSEcCtD
Ponatinib—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000118	0.000533	CcSEcCtD
Ponatinib—Visual impairment—Methotrexate—multiple sclerosis	0.000118	0.000533	CcSEcCtD
Ponatinib—Anaemia—Prednisone—multiple sclerosis	0.000118	0.000533	CcSEcCtD
Ponatinib—Dyspnoea—Triamcinolone—multiple sclerosis	0.000117	0.000531	CcSEcCtD
Ponatinib—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000117	0.00053	CcSEcCtD
Ponatinib—Nervous system disorder—Betamethasone—multiple sclerosis	0.000117	0.00053	CcSEcCtD
Ponatinib—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000117	0.000529	CcSEcCtD
Ponatinib—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000117	0.000529	CcSEcCtD
Ponatinib—Dyspepsia—Triamcinolone—multiple sclerosis	0.000116	0.000524	CcSEcCtD
Ponatinib—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000116	0.000523	CcSEcCtD
Ponatinib—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000116	0.000522	CcSEcCtD
Ponatinib—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000116	0.000522	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—multiple sclerosis	0.000114	0.000517	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—multiple sclerosis	0.000114	0.000514	CcSEcCtD
Ponatinib—Fatigue—Triamcinolone—multiple sclerosis	0.000114	0.000513	CcSEcCtD
Ponatinib—Fatigue—Methylprednisolone—multiple sclerosis	0.000113	0.000512	CcSEcCtD
Ponatinib—Pain—Triamcinolone—multiple sclerosis	0.000113	0.000509	CcSEcCtD
Ponatinib—Angiopathy—Methotrexate—multiple sclerosis	0.000111	0.000502	CcSEcCtD
Ponatinib—Vomiting—Mitoxantrone—multiple sclerosis	0.000111	0.000502	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—multiple sclerosis	0.00011	0.000499	CcSEcCtD
Ponatinib—Hypertension—Prednisone—multiple sclerosis	0.00011	0.000498	CcSEcCtD
Ponatinib—Rash—Mitoxantrone—multiple sclerosis	0.00011	0.000498	CcSEcCtD
Ponatinib—Dermatitis—Mitoxantrone—multiple sclerosis	0.00011	0.000497	CcSEcCtD
Ponatinib—Chills—Methotrexate—multiple sclerosis	0.00011	0.000497	CcSEcCtD
Ponatinib—Headache—Mitoxantrone—multiple sclerosis	0.000109	0.000494	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000109	0.000492	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000109	0.000492	CcSEcCtD
Ponatinib—Myalgia—Prednisone—multiple sclerosis	0.000109	0.000491	CcSEcCtD
Ponatinib—Arthralgia—Prednisone—multiple sclerosis	0.000109	0.000491	CcSEcCtD
Ponatinib—Alopecia—Methotrexate—multiple sclerosis	0.000108	0.000489	CcSEcCtD
Ponatinib—Insomnia—Dexamethasone—multiple sclerosis	0.000108	0.000489	CcSEcCtD
Ponatinib—Insomnia—Betamethasone—multiple sclerosis	0.000108	0.000489	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000108	0.000487	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000107	0.000486	CcSEcCtD
Ponatinib—Paraesthesia—Betamethasone—multiple sclerosis	0.000107	0.000485	CcSEcCtD
Ponatinib—Paraesthesia—Dexamethasone—multiple sclerosis	0.000107	0.000485	CcSEcCtD
Ponatinib—Mental disorder—Methotrexate—multiple sclerosis	0.000107	0.000485	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—multiple sclerosis	0.000107	0.000482	CcSEcCtD
Ponatinib—Erythema—Methotrexate—multiple sclerosis	0.000107	0.000482	CcSEcCtD
Ponatinib—Dyspepsia—Dexamethasone—multiple sclerosis	0.000105	0.000476	CcSEcCtD
Ponatinib—Dyspepsia—Betamethasone—multiple sclerosis	0.000105	0.000476	CcSEcCtD
Ponatinib—Body temperature increased—Triamcinolone—multiple sclerosis	0.000104	0.000471	CcSEcCtD
Ponatinib—Oedema—Prednisone—multiple sclerosis	0.000104	0.00047	CcSEcCtD
Ponatinib—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000104	0.00047	CcSEcCtD
Ponatinib—Decreased appetite—Betamethasone—multiple sclerosis	0.000104	0.00047	CcSEcCtD
Ponatinib—Decreased appetite—Dexamethasone—multiple sclerosis	0.000104	0.00047	CcSEcCtD
Ponatinib—Nausea—Mitoxantrone—multiple sclerosis	0.000104	0.000469	CcSEcCtD
Ponatinib—Infection—Prednisone—multiple sclerosis	0.000103	0.000467	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000103	0.000466	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000103	0.000466	CcSEcCtD
Ponatinib—Back pain—Methotrexate—multiple sclerosis	0.000103	0.000466	CcSEcCtD
Ponatinib—Fatigue—Dexamethasone—multiple sclerosis	0.000103	0.000466	CcSEcCtD
Ponatinib—Fatigue—Betamethasone—multiple sclerosis	0.000103	0.000466	CcSEcCtD
Ponatinib—Pain—Betamethasone—multiple sclerosis	0.000102	0.000462	CcSEcCtD
Ponatinib—Pain—Dexamethasone—multiple sclerosis	0.000102	0.000462	CcSEcCtD
Ponatinib—Nervous system disorder—Prednisone—multiple sclerosis	0.000102	0.000461	CcSEcCtD
Ponatinib—Skin disorder—Prednisone—multiple sclerosis	0.000101	0.000457	CcSEcCtD
Ponatinib—Hyperhidrosis—Prednisone—multiple sclerosis	0.000101	0.000455	CcSEcCtD
Ponatinib—Vision blurred—Methotrexate—multiple sclerosis	0.0001	0.000454	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—multiple sclerosis	9.85e-05	0.000445	CcSEcCtD
Ponatinib—Gastrointestinal pain—Betamethasone—multiple sclerosis	9.77e-05	0.000442	CcSEcCtD
Ponatinib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	9.77e-05	0.000442	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—multiple sclerosis	9.54e-05	0.000431	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	9.48e-05	0.000429	CcSEcCtD
Ponatinib—Dizziness—Prednisolone—multiple sclerosis	9.47e-05	0.000428	CcSEcCtD
Ponatinib—Asthenia—Triamcinolone—multiple sclerosis	9.45e-05	0.000427	CcSEcCtD
Ponatinib—Abdominal pain—Betamethasone—multiple sclerosis	9.44e-05	0.000427	CcSEcCtD
Ponatinib—Abdominal pain—Dexamethasone—multiple sclerosis	9.44e-05	0.000427	CcSEcCtD
Ponatinib—Body temperature increased—Betamethasone—multiple sclerosis	9.44e-05	0.000427	CcSEcCtD
Ponatinib—Body temperature increased—Dexamethasone—multiple sclerosis	9.44e-05	0.000427	CcSEcCtD
Ponatinib—Asthenia—Methylprednisolone—multiple sclerosis	9.43e-05	0.000426	CcSEcCtD
Ponatinib—Insomnia—Prednisone—multiple sclerosis	9.41e-05	0.000426	CcSEcCtD
Ponatinib—Paraesthesia—Prednisone—multiple sclerosis	9.34e-05	0.000422	CcSEcCtD
Ponatinib—Pruritus—Triamcinolone—multiple sclerosis	9.32e-05	0.000421	CcSEcCtD
Ponatinib—Cough—Methotrexate—multiple sclerosis	9.3e-05	0.00042	CcSEcCtD
Ponatinib—Pruritus—Methylprednisolone—multiple sclerosis	9.3e-05	0.00042	CcSEcCtD
Ponatinib—Dyspepsia—Prednisone—multiple sclerosis	9.16e-05	0.000414	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—multiple sclerosis	9.07e-05	0.00041	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—multiple sclerosis	9.07e-05	0.00041	CcSEcCtD
Ponatinib—Decreased appetite—Prednisone—multiple sclerosis	9.04e-05	0.000409	CcSEcCtD
Ponatinib—Rash—Prednisolone—multiple sclerosis	9.03e-05	0.000408	CcSEcCtD
Ponatinib—Dermatitis—Prednisolone—multiple sclerosis	9.02e-05	0.000408	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	9.01e-05	0.000407	CcSEcCtD
Ponatinib—Diarrhoea—Methylprednisolone—multiple sclerosis	8.99e-05	0.000406	CcSEcCtD
Ponatinib—Fatigue—Prednisone—multiple sclerosis	8.97e-05	0.000406	CcSEcCtD
Ponatinib—Headache—Prednisolone—multiple sclerosis	8.97e-05	0.000406	CcSEcCtD
Ponatinib—Constipation—Prednisone—multiple sclerosis	8.9e-05	0.000402	CcSEcCtD
Ponatinib—Dizziness—Triamcinolone—multiple sclerosis	8.71e-05	0.000394	CcSEcCtD
Ponatinib—Dizziness—Methylprednisolone—multiple sclerosis	8.69e-05	0.000393	CcSEcCtD
Ponatinib—Infection—Methotrexate—multiple sclerosis	8.64e-05	0.000391	CcSEcCtD
Ponatinib—Asthenia—Betamethasone—multiple sclerosis	8.57e-05	0.000388	CcSEcCtD
Ponatinib—Asthenia—Dexamethasone—multiple sclerosis	8.57e-05	0.000388	CcSEcCtD
Ponatinib—Nervous system disorder—Methotrexate—multiple sclerosis	8.53e-05	0.000386	CcSEcCtD
Ponatinib—Thrombocytopenia—Methotrexate—multiple sclerosis	8.51e-05	0.000385	CcSEcCtD
Ponatinib—Gastrointestinal pain—Prednisone—multiple sclerosis	8.51e-05	0.000385	CcSEcCtD
Ponatinib—Nausea—Prednisolone—multiple sclerosis	8.51e-05	0.000385	CcSEcCtD
Ponatinib—Pruritus—Dexamethasone—multiple sclerosis	8.45e-05	0.000382	CcSEcCtD
Ponatinib—Pruritus—Betamethasone—multiple sclerosis	8.45e-05	0.000382	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—multiple sclerosis	8.45e-05	0.000382	CcSEcCtD
Ponatinib—Hyperhidrosis—Methotrexate—multiple sclerosis	8.41e-05	0.00038	CcSEcCtD
Ponatinib—Vomiting—Triamcinolone—multiple sclerosis	8.37e-05	0.000379	CcSEcCtD
Ponatinib—Vomiting—Methylprednisolone—multiple sclerosis	8.35e-05	0.000378	CcSEcCtD
Ponatinib—Rash—Triamcinolone—multiple sclerosis	8.3e-05	0.000375	CcSEcCtD
Ponatinib—Dermatitis—Triamcinolone—multiple sclerosis	8.29e-05	0.000375	CcSEcCtD
Ponatinib—Rash—Methylprednisolone—multiple sclerosis	8.28e-05	0.000375	CcSEcCtD
Ponatinib—Dermatitis—Methylprednisolone—multiple sclerosis	8.28e-05	0.000374	CcSEcCtD
Ponatinib—Headache—Triamcinolone—multiple sclerosis	8.25e-05	0.000373	CcSEcCtD
Ponatinib—Headache—Methylprednisolone—multiple sclerosis	8.23e-05	0.000372	CcSEcCtD
Ponatinib—Body temperature increased—Prednisone—multiple sclerosis	8.23e-05	0.000372	CcSEcCtD
Ponatinib—Abdominal pain—Prednisone—multiple sclerosis	8.23e-05	0.000372	CcSEcCtD
Ponatinib—Diarrhoea—Betamethasone—multiple sclerosis	8.17e-05	0.00037	CcSEcCtD
Ponatinib—Diarrhoea—Dexamethasone—multiple sclerosis	8.17e-05	0.00037	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	7.92e-05	0.000358	CcSEcCtD
Ponatinib—Dizziness—Dexamethasone—multiple sclerosis	7.9e-05	0.000357	CcSEcCtD
Ponatinib—Dizziness—Betamethasone—multiple sclerosis	7.9e-05	0.000357	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—multiple sclerosis	7.86e-05	0.000356	CcSEcCtD
Ponatinib—Nausea—Triamcinolone—multiple sclerosis	7.82e-05	0.000354	CcSEcCtD
Ponatinib—Paraesthesia—Methotrexate—multiple sclerosis	7.81e-05	0.000353	CcSEcCtD
Ponatinib—Nausea—Methylprednisolone—multiple sclerosis	7.8e-05	0.000353	CcSEcCtD
Ponatinib—Dyspnoea—Methotrexate—multiple sclerosis	7.75e-05	0.000351	CcSEcCtD
Ponatinib—Dyspepsia—Methotrexate—multiple sclerosis	7.65e-05	0.000346	CcSEcCtD
Ponatinib—Vomiting—Dexamethasone—multiple sclerosis	7.6e-05	0.000343	CcSEcCtD
Ponatinib—Vomiting—Betamethasone—multiple sclerosis	7.6e-05	0.000343	CcSEcCtD
Ponatinib—Decreased appetite—Methotrexate—multiple sclerosis	7.56e-05	0.000342	CcSEcCtD
Ponatinib—Rash—Betamethasone—multiple sclerosis	7.53e-05	0.000341	CcSEcCtD
Ponatinib—Rash—Dexamethasone—multiple sclerosis	7.53e-05	0.000341	CcSEcCtD
Ponatinib—Dermatitis—Betamethasone—multiple sclerosis	7.53e-05	0.00034	CcSEcCtD
Ponatinib—Dermatitis—Dexamethasone—multiple sclerosis	7.53e-05	0.00034	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	7.51e-05	0.000339	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—multiple sclerosis	7.5e-05	0.000339	CcSEcCtD
Ponatinib—Headache—Dexamethasone—multiple sclerosis	7.48e-05	0.000338	CcSEcCtD
Ponatinib—Headache—Betamethasone—multiple sclerosis	7.48e-05	0.000338	CcSEcCtD
Ponatinib—Asthenia—Prednisone—multiple sclerosis	7.47e-05	0.000338	CcSEcCtD
Ponatinib—Pain—Methotrexate—multiple sclerosis	7.44e-05	0.000336	CcSEcCtD
Ponatinib—Pruritus—Prednisone—multiple sclerosis	7.36e-05	0.000333	CcSEcCtD
Ponatinib—Diarrhoea—Prednisone—multiple sclerosis	7.12e-05	0.000322	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methotrexate—multiple sclerosis	7.11e-05	0.000322	CcSEcCtD
Ponatinib—Nausea—Betamethasone—multiple sclerosis	7.1e-05	0.000321	CcSEcCtD
Ponatinib—Nausea—Dexamethasone—multiple sclerosis	7.1e-05	0.000321	CcSEcCtD
Ponatinib—Dizziness—Prednisone—multiple sclerosis	6.88e-05	0.000311	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—multiple sclerosis	6.87e-05	0.000311	CcSEcCtD
Ponatinib—Body temperature increased—Methotrexate—multiple sclerosis	6.87e-05	0.000311	CcSEcCtD
Ponatinib—Vomiting—Prednisone—multiple sclerosis	6.62e-05	0.000299	CcSEcCtD
Ponatinib—Rash—Prednisone—multiple sclerosis	6.56e-05	0.000297	CcSEcCtD
Ponatinib—Dermatitis—Prednisone—multiple sclerosis	6.55e-05	0.000296	CcSEcCtD
Ponatinib—Headache—Prednisone—multiple sclerosis	6.52e-05	0.000295	CcSEcCtD
Ponatinib—Asthenia—Methotrexate—multiple sclerosis	6.24e-05	0.000282	CcSEcCtD
Ponatinib—Nausea—Prednisone—multiple sclerosis	6.18e-05	0.000279	CcSEcCtD
Ponatinib—Pruritus—Methotrexate—multiple sclerosis	6.15e-05	0.000278	CcSEcCtD
Ponatinib—Diarrhoea—Methotrexate—multiple sclerosis	5.95e-05	0.000269	CcSEcCtD
Ponatinib—Dizziness—Methotrexate—multiple sclerosis	5.75e-05	0.00026	CcSEcCtD
Ponatinib—Vomiting—Methotrexate—multiple sclerosis	5.53e-05	0.00025	CcSEcCtD
Ponatinib—Rash—Methotrexate—multiple sclerosis	5.48e-05	0.000248	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—multiple sclerosis	5.48e-05	0.000248	CcSEcCtD
Ponatinib—Headache—Methotrexate—multiple sclerosis	5.45e-05	0.000246	CcSEcCtD
Ponatinib—Nausea—Methotrexate—multiple sclerosis	5.17e-05	0.000234	CcSEcCtD
Ponatinib—SRC—Axon guidance—IL6—multiple sclerosis	7.18e-06	3.03e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CCR5—multiple sclerosis	7.17e-06	3.03e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.15e-06	3.02e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—APOE—multiple sclerosis	7.15e-06	3.02e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—APOE—multiple sclerosis	7.13e-06	3.01e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—BCHE—multiple sclerosis	7.12e-06	3.01e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SPP1—multiple sclerosis	7.11e-06	3e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—IL6—multiple sclerosis	7.09e-06	3e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL2—multiple sclerosis	7.09e-06	2.99e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—ALB—multiple sclerosis	7.08e-06	2.99e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—IL6—multiple sclerosis	7.07e-06	2.99e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—IL6—multiple sclerosis	7.06e-06	2.98e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL1B—multiple sclerosis	7.05e-06	2.98e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—CD4—multiple sclerosis	7.05e-06	2.98e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL1B—multiple sclerosis	7.03e-06	2.97e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—CD4—multiple sclerosis	7.03e-06	2.97e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—IL6—multiple sclerosis	7.03e-06	2.97e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL2—multiple sclerosis	7.03e-06	2.97e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL2—multiple sclerosis	7.01e-06	2.96e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—HLA-A—multiple sclerosis	6.98e-06	2.95e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IFNG—multiple sclerosis	6.96e-06	2.94e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GPC5—multiple sclerosis	6.95e-06	2.94e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CD80—multiple sclerosis	6.94e-06	2.93e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IFNG—multiple sclerosis	6.92e-06	2.93e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—TLR4—multiple sclerosis	6.92e-06	2.92e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCR5—multiple sclerosis	6.92e-06	2.92e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HLA-DRB1—multiple sclerosis	6.91e-06	2.92e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL2RA—multiple sclerosis	6.82e-06	2.88e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CD80—multiple sclerosis	6.81e-06	2.88e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—TGFB1—multiple sclerosis	6.8e-06	2.87e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD4—multiple sclerosis	6.72e-06	2.84e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MMP9—multiple sclerosis	6.71e-06	2.83e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD4—multiple sclerosis	6.69e-06	2.83e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TGFB1—multiple sclerosis	6.67e-06	2.82e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—MAPK1—multiple sclerosis	6.67e-06	2.82e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CD80—multiple sclerosis	6.66e-06	2.81e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—MAPK1—multiple sclerosis	6.65e-06	2.81e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—ICAM1—multiple sclerosis	6.63e-06	2.8e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—POMC—multiple sclerosis	6.59e-06	2.79e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—MAPK1—multiple sclerosis	6.54e-06	2.76e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.52e-06	2.76e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—APOE—multiple sclerosis	6.52e-06	2.75e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—POMC—multiple sclerosis	6.47e-06	2.74e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL10—multiple sclerosis	6.47e-06	2.73e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CD80—multiple sclerosis	6.47e-06	2.73e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CD80—multiple sclerosis	6.45e-06	2.73e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCL2—multiple sclerosis	6.45e-06	2.73e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL6—multiple sclerosis	6.44e-06	2.72e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CD86—multiple sclerosis	6.39e-06	2.7e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD80—multiple sclerosis	6.38e-06	2.7e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—TNF—multiple sclerosis	6.35e-06	2.68e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—STAT3—multiple sclerosis	6.34e-06	2.68e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCL2—multiple sclerosis	6.33e-06	2.68e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCL5—multiple sclerosis	6.29e-06	2.66e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—APOE—multiple sclerosis	6.29e-06	2.66e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—IL6—multiple sclerosis	6.24e-06	2.64e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—STAT3—multiple sclerosis	6.23e-06	2.63e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—IL6—multiple sclerosis	6.21e-06	2.62e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL1B—multiple sclerosis	6.2e-06	2.62e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL2—multiple sclerosis	6.18e-06	2.61e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL1B—multiple sclerosis	6.18e-06	2.61e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL2—multiple sclerosis	6.17e-06	2.61e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—BCHE—multiple sclerosis	6.16e-06	2.6e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL2—multiple sclerosis	6.15e-06	2.6e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—POMC—multiple sclerosis	6.14e-06	2.6e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—POMC—multiple sclerosis	6.13e-06	2.59e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—TYK2—multiple sclerosis	6.09e-06	2.57e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCL2—multiple sclerosis	6.01e-06	2.54e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCL2—multiple sclerosis	6e-06	2.53e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—APOE—multiple sclerosis	5.98e-06	2.52e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—STAT3—multiple sclerosis	5.96e-06	2.52e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—IL6—multiple sclerosis	5.95e-06	2.51e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—STAT3—multiple sclerosis	5.91e-06	2.5e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—STAT3—multiple sclerosis	5.9e-06	2.49e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CD80—multiple sclerosis	5.9e-06	2.49e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—MAPK1—multiple sclerosis	5.89e-06	2.49e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TYK2—multiple sclerosis	5.86e-06	2.47e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—STAT3—multiple sclerosis	5.86e-06	2.47e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MMP9—multiple sclerosis	5.84e-06	2.47e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SPP1—multiple sclerosis	5.83e-06	2.46e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—MAPK1—multiple sclerosis	5.77e-06	2.44e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—RRM1—multiple sclerosis	5.76e-06	2.43e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TYK2—multiple sclerosis	5.75e-06	2.43e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—STAT3—multiple sclerosis	5.75e-06	2.43e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IFNG—multiple sclerosis	5.7e-06	2.41e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CD80—multiple sclerosis	5.69e-06	2.4e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCR5—multiple sclerosis	5.67e-06	2.4e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—MAPK1—multiple sclerosis	5.66e-06	2.39e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CD86—multiple sclerosis	5.66e-06	2.39e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—IL6—multiple sclerosis	5.63e-06	2.38e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—TYK2—multiple sclerosis	5.62e-06	2.38e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2RA—multiple sclerosis	5.59e-06	2.36e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL5—multiple sclerosis	5.57e-06	2.35e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MYC—multiple sclerosis	5.54e-06	2.34e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TGFB1—multiple sclerosis	5.53e-06	2.34e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD4—multiple sclerosis	5.51e-06	2.33e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TYK2—multiple sclerosis	5.46e-06	2.31e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—STAT3—multiple sclerosis	5.46e-06	2.31e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TYK2—multiple sclerosis	5.44e-06	2.3e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—STAT3—multiple sclerosis	5.44e-06	2.3e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—MYC—multiple sclerosis	5.44e-06	2.3e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—TGFB1—multiple sclerosis	5.43e-06	2.29e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MAPK1—multiple sclerosis	5.42e-06	2.29e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—POMC—multiple sclerosis	5.41e-06	2.28e-05	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	5.4e-06	2.28e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—TYK2—multiple sclerosis	5.39e-06	2.28e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—MAPK1—multiple sclerosis	5.37e-06	2.27e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—BCHE—multiple sclerosis	5.37e-06	2.27e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—MAPK1—multiple sclerosis	5.36e-06	2.26e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—MYC—multiple sclerosis	5.34e-06	2.26e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—TGFB1—multiple sclerosis	5.33e-06	2.25e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—MAPK1—multiple sclerosis	5.32e-06	2.25e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCL2—multiple sclerosis	5.29e-06	2.23e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—MAPK1—multiple sclerosis	5.23e-06	2.21e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—STAT3—multiple sclerosis	5.2e-06	2.2e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—STAT3—multiple sclerosis	5.19e-06	2.19e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—STAT3—multiple sclerosis	5.18e-06	2.19e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SPP1—multiple sclerosis	5.16e-06	2.18e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—APOE—multiple sclerosis	5.16e-06	2.18e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—POMC—multiple sclerosis	5.13e-06	2.17e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—IL6—multiple sclerosis	5.12e-06	2.17e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—IL6—multiple sclerosis	5.11e-06	2.16e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL1B—multiple sclerosis	5.09e-06	2.15e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CD4—multiple sclerosis	5.08e-06	2.15e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—MYC—multiple sclerosis	5.07e-06	2.14e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL2—multiple sclerosis	5.07e-06	2.14e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—BCHE—multiple sclerosis	5.06e-06	2.14e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—TGFB1—multiple sclerosis	5.06e-06	2.14e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—MYC—multiple sclerosis	5.06e-06	2.14e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IFNG—multiple sclerosis	5.05e-06	2.13e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—TGFB1—multiple sclerosis	5.05e-06	2.13e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCR5—multiple sclerosis	5.02e-06	2.12e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—TYK2—multiple sclerosis	4.98e-06	2.1e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—MAPK1—multiple sclerosis	4.96e-06	2.1e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—MAPK1—multiple sclerosis	4.95e-06	2.09e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2RA—multiple sclerosis	4.95e-06	2.09e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD4—multiple sclerosis	4.87e-06	2.06e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL2—multiple sclerosis	4.87e-06	2.06e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MYC—multiple sclerosis	4.83e-06	2.04e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TGFB1—multiple sclerosis	4.81e-06	2.03e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TYK2—multiple sclerosis	4.8e-06	2.03e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL2—multiple sclerosis	4.79e-06	2.02e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—MAPK1—multiple sclerosis	4.73e-06	2e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MAPK1—multiple sclerosis	4.72e-06	1.99e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—MAPK1—multiple sclerosis	4.71e-06	1.99e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ALB—multiple sclerosis	4.68e-06	1.98e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CD80—multiple sclerosis	4.66e-06	1.97e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MMP9—multiple sclerosis	4.61e-06	1.95e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APOE—multiple sclerosis	4.57e-06	1.93e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL2—multiple sclerosis	4.54e-06	1.92e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL2—multiple sclerosis	4.53e-06	1.91e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MMP9—multiple sclerosis	4.53e-06	1.91e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—IL6—multiple sclerosis	4.53e-06	1.91e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL1B—multiple sclerosis	4.5e-06	1.9e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CD4—multiple sclerosis	4.5e-06	1.9e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL2—multiple sclerosis	4.48e-06	1.89e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—POMC—multiple sclerosis	4.43e-06	1.87e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL6—multiple sclerosis	4.43e-06	1.87e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL6—multiple sclerosis	4.35e-06	1.84e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCL2—multiple sclerosis	4.34e-06	1.83e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—multiple sclerosis	4.3e-06	1.82e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—multiple sclerosis	4.29e-06	1.81e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APOE—multiple sclerosis	4.28e-06	1.81e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—STAT3—multiple sclerosis	4.26e-06	1.8e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL6—multiple sclerosis	4.16e-06	1.76e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—multiple sclerosis	4.13e-06	1.74e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CD80—multiple sclerosis	4.13e-06	1.74e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—multiple sclerosis	4.12e-06	1.74e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—STAT3—multiple sclerosis	4.1e-06	1.73e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—multiple sclerosis	4.09e-06	1.73e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—STAT3—multiple sclerosis	4.03e-06	1.7e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—multiple sclerosis	4.02e-06	1.7e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL2—multiple sclerosis	4e-06	1.69e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TYK2—multiple sclerosis	3.94e-06	1.66e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—STAT3—multiple sclerosis	3.94e-06	1.66e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—POMC—multiple sclerosis	3.92e-06	1.66e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK1—multiple sclerosis	3.88e-06	1.64e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL2—multiple sclerosis	3.84e-06	1.62e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—STAT3—multiple sclerosis	3.82e-06	1.61e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—multiple sclerosis	3.81e-06	1.61e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—STAT3—multiple sclerosis	3.81e-06	1.61e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—multiple sclerosis	3.81e-06	1.61e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—multiple sclerosis	3.8e-06	1.61e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TGFB1—multiple sclerosis	3.8e-06	1.61e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—multiple sclerosis	3.78e-06	1.6e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—STAT3—multiple sclerosis	3.77e-06	1.59e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—multiple sclerosis	3.74e-06	1.58e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TGFB1—multiple sclerosis	3.73e-06	1.58e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK1—multiple sclerosis	3.73e-06	1.58e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOE—multiple sclerosis	3.71e-06	1.57e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—POMC—multiple sclerosis	3.68e-06	1.55e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK1—multiple sclerosis	3.66e-06	1.55e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—multiple sclerosis	3.66e-06	1.55e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFB1—multiple sclerosis	3.65e-06	1.54e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—multiple sclerosis	3.63e-06	1.53e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—multiple sclerosis	3.63e-06	1.53e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—multiple sclerosis	3.62e-06	1.53e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK1—multiple sclerosis	3.58e-06	1.51e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—multiple sclerosis	3.55e-06	1.5e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TGFB1—multiple sclerosis	3.54e-06	1.5e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—multiple sclerosis	3.54e-06	1.5e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TGFB1—multiple sclerosis	3.53e-06	1.49e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TYK2—multiple sclerosis	3.48e-06	1.47e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—STAT3—multiple sclerosis	3.48e-06	1.47e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK1—multiple sclerosis	3.47e-06	1.47e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK1—multiple sclerosis	3.47e-06	1.46e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK1—multiple sclerosis	3.43e-06	1.45e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STAT3—multiple sclerosis	3.36e-06	1.42e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ALB—multiple sclerosis	3.35e-06	1.42e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—BCHE—multiple sclerosis	3.31e-06	1.4e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—multiple sclerosis	3.28e-06	1.38e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—multiple sclerosis	3.24e-06	1.37e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOE—multiple sclerosis	3.23e-06	1.36e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFB1—multiple sclerosis	3.23e-06	1.36e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—POMC—multiple sclerosis	3.19e-06	1.35e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK1—multiple sclerosis	3.17e-06	1.34e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—multiple sclerosis	3.12e-06	1.32e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TGFB1—multiple sclerosis	3.12e-06	1.32e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—multiple sclerosis	3.1e-06	1.31e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK1—multiple sclerosis	3.06e-06	1.29e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOE—multiple sclerosis	3.04e-06	1.29e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—multiple sclerosis	2.98e-06	1.26e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ALB—multiple sclerosis	2.9e-06	1.23e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—multiple sclerosis	2.9e-06	1.23e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—multiple sclerosis	2.86e-06	1.21e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—multiple sclerosis	2.81e-06	1.19e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—POMC—multiple sclerosis	2.78e-06	1.17e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STAT3—multiple sclerosis	2.76e-06	1.16e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—multiple sclerosis	2.75e-06	1.16e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—multiple sclerosis	2.74e-06	1.16e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—multiple sclerosis	2.67e-06	1.13e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—multiple sclerosis	2.66e-06	1.13e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—multiple sclerosis	2.64e-06	1.11e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—POMC—multiple sclerosis	2.62e-06	1.1e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—multiple sclerosis	2.56e-06	1.08e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TGFB1—multiple sclerosis	2.55e-06	1.08e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ALB—multiple sclerosis	2.53e-06	1.07e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK1—multiple sclerosis	2.51e-06	1.06e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT3—multiple sclerosis	2.44e-06	1.03e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—multiple sclerosis	2.43e-06	1.03e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ALB—multiple sclerosis	2.38e-06	1.01e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—multiple sclerosis	2.35e-06	9.92e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—multiple sclerosis	2.27e-06	9.58e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFB1—multiple sclerosis	2.26e-06	9.56e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK1—multiple sclerosis	2.22e-06	9.37e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOE—multiple sclerosis	1.99e-06	8.41e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—multiple sclerosis	1.93e-06	8.13e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—POMC—multiple sclerosis	1.71e-06	7.22e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—multiple sclerosis	1.7e-06	7.2e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALB—multiple sclerosis	1.56e-06	6.59e-06	CbGpPWpGaD
